The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Mochalova A.S.
Petrovsky Russian Scientific Center of Surgery;
Group of Companies “Medsi” JSC — Medsi Clinical Hospital in Otradnoe
Alieskerov M.V.
Group of Companies “Medsi” JSC — Medsi Clinical Hospital in Otradnoe
Features of the course of COVID-19 in patients with cancer in the intensive care unit
Journal: Russian Journal of Pain. 2024;22(3): 55‑62
Read: 743 times
To cite this article:
Vlasenkova AA, Mochalova AS, Linnik DV, Akselrod BA, Alieskerov MV. Features of the course of COVID-19 in patients with cancer in the intensive care unit. Russian Journal of Pain.
2024;22(3):55‑62. (In Russ.)
https://doi.org/10.17116/pain20242203155
Today, oncological diseases are widespread throughout the world, which causes increased attention from doctors to this category of patients. According to numerous studies, the infection rate of cancer and non-cancer patients with COVID-19 infection is comparable, but there is evidence that people with malignant diseases have an increased risk of mortality from complications caused by the SARS-CoV-2 virus.
To study the the features of the course of COVID-19 infection in patients with malignant oncological diseases in the intensive care unit.
The study included clinical and laboratory data from 54 cancer patients aged 18 to 95 years (mean age 66.4±2.7 years) who were infected with COVID-19 and were in the intensive care unit. Patients received one of the treatment options for coronavirus infection with monoclonal antibodies or an antiviral drug in combination with a monoclonal antibody. Respiratory support included non-invasive ventilation (NIV) and mechanical ventilation (adaptive lung ventilation — ALV). The results of instrumental studies and laboratory data before and after the start of treatment were compared, and the degree of mortality was assessed. At the time of the study, patients with malignant neoplasms did not receive therapy for the underlying disease due to the severity of their condition and their stay in the intensive care unit.
According to the results obtained, the presence of cancer did not have a statistically significant effect on the duration of hospitalization for novel coronavirus infection (p=0.55). As a result of the treatment of COVID-19, it was possible to achieve a significant decrease only in the level of C-reactive protein from 65.5±16.9 g/l to 40.9±20.0 g/l (p=0.007), while in 22 people (61.1%), an elevated level of this inflammatory marker remained. The presence of oncological pathology was not associated with the level of CRP (Fisher’s test p=0.88), leukocytes (Fisher’s test p=0.26), and lymphocytes (Fisher’s test p=0.18) before treatment. In cancer patients, IL-6 and TNF-α levels remained above the normal range throughout the course of the disease and reached a second peak in the fourth or fifth week. It was found that deceased cancer patients had significantly more severe immune dysregulation compared to discharged patients, including IL-2, IL-6, IL-8, IL-10 and TNF-α. Mortality among cancer patients due to COVID-19 infection was 1.9% (n=1).
Patients with malignant neoplasms are at high risk of developing a severe course of COVID-19 infection, due to the characteristics of the immune status, as well as the severity of the underlying disease.
Authors:
Mochalova A.S.
Petrovsky Russian Scientific Center of Surgery;
Group of Companies “Medsi” JSC — Medsi Clinical Hospital in Otradnoe
Alieskerov M.V.
Group of Companies “Medsi” JSC — Medsi Clinical Hospital in Otradnoe
Received:
20.07.2024
Accepted:
29.07.2024
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.